

**HIV-1 INTEGRASE INHIBITORS:
A FORMAL TOTAL SYNTHESIS OF
LITHOSPERMIC ACID AND
SYNTHETIC STUDIES TOWARDS
INTEGRAMYCIN**

A Thesis submitted in fulfilment of the
requirements for admission to the degree of

Doctor of Philosophy

By

Joshua Fischer



School of Chemistry, University of Sydney

December 2007



Hofstadter's Law: It always takes longer than you expect, even when you take into account Hofstadter's Law.

– Douglas Hofstadter

DECLARATION

This thesis is a summary of work carried out in the School of Chemistry, The University of Sydney, and the Ian Wark Laboratories, CSIRO Clayton, under the supervision of Dr Mark J. Coster, A/Prof Katrina A. Jolliffe and Dr Paul Savage between March 2004 and November 2007.

This thesis contains no material previously published or extracted in whole or in part from a thesis presented by me for any other degree or diploma. No other person's work has been used without due acknowledgement and every effort has been made to acknowledge previously published material. This thesis contains less than 80000 words.

Sections of original work described in this manuscript have been published in a peer-reviewed scientific journal, namely:

“Regioselective Reduction of 3-methoxymaleimides: An Efficient Method for the Synthesis of Methyl 5-hydroxytetramates” Issa, F; Fischer, J; Turner, P; Coster, M.J.; *J. Org. Chem.*, **2006**, *71*, 4703–4705.

Joshua Fischer
December 2007

ABSTRACT

This thesis describes synthetic studies towards the HIV-1 integrase inhibitory natural products lithospermic acid and integramycin, resulting in a formal total synthesis of the former.

A modular, flexible and convergent synthetic strategy to lithospermic acid was devised. In this approach, a Sonogashira coupling was used to unite the C₁–C₇ and C₂₀–C₂₇ fragments that were subsequently manipulated to then participate in the key step of the synthesis, a palladium-mediated carbonylative annulation. Reduction of the benzofuran nucleus with magnesium in methanol then provided the desired dihydrobenzofuran core of lithospermic acid. Various protecting group strategies were investigated to complete this sequence in an efficient manner. Further synthetic manipulations afforded the complete C₁–C₉/C₁₉–C₂₇ fragment, which was united with the C₁₀–C₁₈ fragment to deliver the entire carbon skeleton of lithospermic acid. A two step deprotection sequence was undertaken, however, complications with the final deprotective step prevented definitive proof that the total synthesis of lithospermic acid had been achieved. An alternate protecting group strategy was sought, and a formal total synthesis of lithospermic acid was achieved by intercepting an advanced intermediate from a previous total synthesis. Several strategies for the enantioselective synthesis of the dihydrobenzofuran core of lithospermic acid were evaluated, however, none proved successful.

A synthetic route towards the tetramic acid subunit of integramycin was also investigated. 3-Methoxymaleimide was constructed using known chemistry, and the regioselective reduction of this ring system was developed. Attempts to further functionalise this ring system were thwarted by difficulties associated with handling. The scope of the regioselective reduction was investigated on an array of *N*-substituted methoxymaleimides with the procedure found to be generally high yielding and highly regioselective.

ACKNOWLEDGEMENTS

It is with great pleasure that I am able to acknowledge an array of people that I have crossed paths with over the years. Firstly, I must thank my supervisor, Dr Mark Coster, for all his encouragement, enthusiasm, support and encyclopedic knowledge of organic chemistry. It has been a pleasure and a true privilege to work with him. I'd also like to thank Dr Paul Savage for all his helpful suggestions, A/Prof. Katrina Jolliffe and A/Prof. Margaret Harding for all their guidance and support.

I would also like to take this opportunity to thank all the members of the Coster research group and beyond at the School of Chemistry: Cody, Hendra, Sam, Sean, Fatiah, Adam, Conor, Cillian, Jill, Shane and Claire to name but a few. They have all helped in so many ways, but particularly through their friendship. Particular thanks must go to my friends Aaron, Kylee, Katie and Kaitlin for, among many other things, their help in proof-reading this manuscript. Special mentions are especially warranted for my friends Kylee, whose help over this past year has been extraordinary (practical jokes included), and Katie, who has been an endless source of advice and support (and entertainment) since I started this adventure.

A great debt is owed to the following people for their technical assistance: Dr Ian Luck (and staff) at the NMR facility for running NMR experiments, and always having time to help; Dr Kelvin Picker for HPLC expertise; and Prof. Chris Burrell and Dr Li Peng for biological testing of my samples. I must also include Bruce and Carlo for their efforts and general assistance in the service room.

My thanks also go to two special teachers, Mrs Wilson and Mr Evans for inspiring me to aim high and to strive to get there.

I must acknowledge various bodies and sources of financial support: The School of Chemistry, University of Sydney; Department of Education, Science and Training; CSIRO Postgraduate Studentship; Agnes Campbell Postgraduate Prizes; and, in particular, Mrs Dorothy Lamberton for the Lamberton Scholarship.

To the world outside the confines of the chemistry building: Ryan, Matt, Mark P, Gordon, Ryan and Fe, Felicity, Derek, Luke, Mark and others who have offered unwavering support, patience and outstanding friendships. I thank them all dearly.

My sincerest and heartfelt thanks must go to my Mum and Dad, who have provided me with boundless opportunities and endless support and encouragement. Thanks for leaving me wantless in life. Also to Janah and Luke, Omi and Opi, Nana and Pa, Jean and Karl and all my extended family, I am grateful for their solace and support. And finally, thanks to Danielle, my wife and my all. I certainly could not have achieved this without her by my side.

TABLE OF CONTENTS

Declaration	i
Abstract	ii
Acknowledgements	iii
Table of Contents	iv
Abbreviations	vii
Compound Numbering	x

–Chapter 1– Introduction

1.1 AIDS	2
1.1.1 HIV and its Effects	2
1.1.2 The HIV Lifecycle	3
1.1.3 Current Treatments	4
1.1.4 HIV-1 Integrase as a Therapeutic Target	7
1.1.5 Function of HIV-1 Integrase	8
1.1.6 Structure of HIV-1 Integrase	8
1.2 Inhibitors of HIV-1 Integrase	10
1.2.1 Hydroxylated Aromatic Inhibitors (Catechols)	10
1.2.2 Diketo Acid Inhibitors	12
1.3 Lithospermic Acid	15
1.3.1 A Historical Account	15
1.3.2 Lithospermic Acid as an Integrase Inhibitor	16
1.3.3 Previous Synthetic Efforts	17
1.4 Integramycin	23
1.5 Project Aims	24

–Chapter 2– Model System studies of Lithospermic Acid and Initial Investigations Into Protecting Group Strategy

2.1 Retrosynthetic Analysis of Lithospermic Acid	26
2.2 Synthesis of the C₁–C₇ Aryl Iodide	27
2.3 Synthetic Studies on a Model System	27
2.3.1 Sonogashira Coupling	28
2.3.2 A Troublesome Deprotection	30
2.3.3 The Carbonylative Annulation	33
2.3.4 Tandem Deprotection and Carbonylative Annulation	35
2.3.5 Masking the Aldehyde	36
2.4 Towards a System Possessing the Oxygenation of the Natural Product	37
2.4.1 Synthesis of an Oxygenated C ₂₀ –C ₂₇ Arylalkyne	37
2.4.2 Sonogashira Coupling	39
2.4.3 De-acetylation and Carbonylative Annulation	40
2.5 Summary	44

–Chapter 3– Synthesis of the C₁–C₉/C₁₉–C₂₇ Fragment of Lithospermic Acid

3.1 An Alternative Protecting Group Strategy	47
3.1.1 Synthesis of the C ₂₀ –C ₂₇ Arylalkyne	47
3.1.2 Sonogashira Coupling	48
3.1.3 Synthesis of the <i>ortho</i> -hydroxydiarylalkyne	49
3.1.4 Two step Reduction then De-acetylation	52
3.1.5 The Carbonylative Annulation	53
3.1.6 Exclusive Formation of the Lactone	54

3.1.7	Probing the Formation of the Lactone	56
3.2	Selective Deprotection Studies	58
3.3	Reduction of the Benzofuran Ring system	60
3.3.1	Aldehyde Protection as the Dioxolane	62
3.3.2	Aldehyde Protection as the Dioxane	63
3.4	Accessing the 2,3-dihydrobenzofuran	64
3.5	Completing the C ₁ -C ₉ /C ₁₉ -C ₂₇ Fragment	67
3.6	Biological Evaluation of Phenol 123 and Catechol 124	68
3.7	Summary	69

–Chapter 4–

Initial Approach to a Total Synthesis of Lithospermic Acid

4.1	Construction of the C ₁₀ -C ₁₈ Fragment	71
4.2	Uniting the C ₁ -C ₉ /C ₁₉ -C ₂₇ and C ₁₀ -C ₁₈ Fragments	75
4.3	Deprotection Stage 1: Ester Cleavage	76
4.4	Deprotection Stage 2: The Final Deprotection	77
4.5	Initial Investigations into a New Protecting Group Strategy	81
4.6	Summary	83

–Chapter 5–

A Formal Total Synthesis of (+)-Lithospermic Acid

5.1	Introductory Remarks	85
5.2	Synthesis of C ₂₀ -C ₂₇ ArylAlkyne	85
5.3	Sonogashira Coupling	86
5.4	Aldehyde Protection and Deacetylation	86
5.5	The Carbonylative Annulation Reaction	87
5.6	Reduction to give the 2,3-Dihydrobenzofuran	88
5.7	Completion of a Formal Total Synthesis of (+)-Lithospermic Acid	90
5.8	Summary	93

–Chapter 6–

Synthetic Studies Towards an Enantioenriched C₁-C₉/C₁₉-C₂₇ Fragment of Lithospermic Acid

6.1	Introductory remarks	96
6.2	Chiral Auxiliary	96
6.2.1	Transesterification	96
6.2.2	Two Step Conversion to the Chiral Ester	99
6.2.3	Chiral Acetal Approach	103
6.3	Resolution of the Racemate	106
6.3.1	Reduction to Racemic 2,3-Dihydrobenzofuran then Separation	106
6.4	Catalytic Enantioselective Reduction	110
6.4.1	Attempted Reduction with Pfaltz's Catalyst	110
6.5	Summary	112

–Chapter 7–

Synthetic Studies Towards the Tetramic Acid Subunit of Integramycin

7.1	Retrosynthetic Analysis of Integramycin	114
7.2	Preparation of 3-Methoxymaleimide	115
7.3	The Regioselective Reduction of 3-Methoxymaleimide	117
7.4	Attempted Functionalisation of the C4 Position	120
7.5	Attempted Demethylation	121
7.6	Further Exploration into Reagents for the Regioselective Reduction	123
7.7	Further Investigations into the Scope of the Regioselective Reduction	125
7.7.1	Synthesis of Reduction Precursors	125

7.7.2	Scope of the Regioselective Reduction	126
7.8	Biological Evaluation of Tetramic Acid Fragments	128
7.9	Summary and Future Work	128

–Chapter 8– Experimental

8.1	General Methods	130
8.2	Synthesis of Reagents	132
8.3	Synthesis of Compounds from Chapter 2	135
8.4	Synthesis of Compounds from Chapter 3	149
8.5	Synthesis of Compounds from Chapter 4	170
8.6	Synthesis of Compounds from Chapter 5	176
8.7	Synthesis of Compounds from Chapter 6	186
8.8	Synthesis of Compounds from Chapter 7	192
	References	203
	Appendix A	211
	Appendix B	214

ABBREVIATIONS

%	percentage yield
Δ	reflux
$^{\circ}\text{C}$	degree/s Celsius
\AA	Angstrom, 10^{-10} metres
Ac	acetyl
AIDS	acquired immunodeficiency syndrome
Anal.	analysis
aq.	aqueous
Ar	aryl or argon
Asp	aspartic acid
BAr _F	$\text{B}(2,3\text{-(CF}_3)_2\text{C}_6\text{H}_3)_4$
BBN	9-Borabicyclo[3.3.1]nonane
Bn	benzyl
br	broad
Bu	butyl
C	cysteine
CCR5	chemokine receptor 5
CC ₁₀₀	cytotoxic concentration for 100% of cells
ca.	circa (approximately)
calc.	calculated
cm ⁻¹	reciprocal centimeters
coe	cyclooctene
Cys	cysteine
δ	chemical shift
D	aspartic acid
d	doublet/s
DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
DCE	1,2-dichloroethane
DEAD	diethyl azodicarboxylate
DIAD	diisopropyl azodicarboxylate
DKA	diketoacid
DMAP	4-(dimethylamino)pyridine
DMF	<i>N,N</i> -dimethylformamide

DNA	deoxyribonucleic acid
dppp	1,3-bisdiphenylphosphinopropane
DIBAL–H	diisobutylaluminium hydride
E	glutamic acid
<i>ee</i>	enantiomeric excess
EDC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
EI	electron impact
equiv.	molar equivalent(s)
Et	ethyl
eV	electron Volts
Glu	glutamic acid
g	gram
H	histidine
h	hour/s
HAART	Highly active anti-retroviral therapy
His	histidine
HIV	human immunodeficiency virus
HRMS	high resolution mass spectrometry
Hz	Hertz
IC ₅₀	concentration required to inhibit a given biological process by 50%
<i>i</i> -Pr	isopropyl
IN	integrase
IR	infrared
<i>J</i>	coupling constant
K	Kelvin
L	litre
μ	micro
m	multiplet
M	molar
M ⁺ , M ⁺⁺	molecular ion
Me	methyl
min	minutes
MHz	megahertz
mmol	millimole
mol	mole


m.p.	melting point
MS	mass spectrometry
m/z	mass to charge ratio
<i>n</i> -BuLi	<i>n</i> -butyllithium
NMR	nuclear magnetic resonance
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
Ph	phenyl
PI	protease inhibitor
PIC	pre-integration complex
PMHS	polymethylhydrosiloxane
ppm	parts per million
<i>p</i> -TsOH	<i>para</i> -toluenesulfonic acid
pyr	pyridine
q	quartet
quant.	quantitative (yield)
R	unspecified functional group
R _f	retention factor
RNA	ribonucleic acid
rt	room temperature (25 °C)
s	singlet
t	triplet
<i>t</i> -AmOH	<i>tert</i> -amyl alcohol
TBAF	tetrabutylammonium fluoride
TBDPSE	<i>tert</i> -butyldiphenylsilylethyl
TBS	<i>tert</i> -butyldimethylsilyl
TFA	trifluoroacetic acid
THF	tetrahydrofuran
tlc	thin layer chromatography
TMS	trimethylsilyl; tetramethylsilane
Ts	tosyl
USFDA	United States Food and Drug Administration
v/v, w/v	volume per volume, weight per volume

COMPOUND NUMBERING


In general, the naming and numbering priorities used throughout this manuscript are those set down by IUPAC. Otherwise, the numbering system of lithospermic acid (**21**) and integramycin (**47**), set forth by Kelley *et al.*⁴³ and Singh *et al.*⁵⁴ respectively, are employed and are shown below.

When discussing the 2,3-disubstituted-2,3-dihydrobenzofuran ring systems, the designations *cis*- and *trans*- refer to the relative configuration of the substituents, and unless otherwise noted, refer to the racemate. Further to this, diastereomeric compounds are assigned the same compound number but are distinguished by the stereochemical descriptor in the prefix.

When discussing the tetramic acid subunit (C_1 - C_3) of integramycin (**47**), IUPAC numbering designations are *not* utilised. For clarity, the numbering system of the parent compound, integramycin, (**47**) is utilised consistently throughout.



lithospermic acid (**21**)



integramycin (**47**)